While localized primary tumors are frequently treatable through surgery or targeted therapies, the systemic spread of cancer cells to distant organs—metastasis—accounts for the vast majority of cancer-related mortality. As noted by Yajun Liu et al. in Overexpression of human osteopontin increases cell proliferation and migration in human embryo kidney-293 cells, metastasis is responsible for approximately 90% of cancer deaths.
This lethal progression is not a random shedding of cells, but a highly coordinated, multi-step biological program. To colonize a distant organ, a cancer cell must detach from its neighbors, remodel its internal skeleton, chew through the surrounding tissue matrix, survive the harsh environment of the circulatory system, and ultimately adapt to a foreign tissue microenvironment. Understanding the molecular switches that turn a sedentary tumor cell into an invasive, migratory agent is the central focus of modern oncology.
The Identity Shift: Epithelial-Mesenchymal Transition
To become mobile, stationary epithelial cells must undergo a profound identity shift known as the epithelial-mesenchymal transition (EMT). During EMT, cells shed their rigid cell-to-cell adhesions, alter their shape, and acquire the migratory properties of mesenchymal cells.
This transition is orchestrated by master transcription factors like Snail and Snail2, which act as genomic switches to turn off epithelial genes and turn on migratory ones. Under normal conditions, these factors are tightly suppressed by epigenetic and post-transcriptional brakes. For instance, Qing Nie et al. in Histone Deacetylases Inhibit the Snail2-Mediated EMT During Metastasis of Hepatocellular Carcinoma Cells show that histone deacetylases act as epigenetic brakes on Snail2 to prevent liver cancer spread. Similarly, Yicheng Xiong et al. in MicroRNA-30b targets Snail to impede epithelial-mesenchymal transition in pancreatic cancer stem cells demonstrate that microRNA-30b directly targets and suppresses Snail to block pancreatic cancer cell migration.
When these regulatory brakes fail, cells remodel their physical architecture to generate the mechanical force needed for movement. Rui Li et al. in LIM kinase 1 interacts with myosin-9 and alpha-actinin-4 and promotes colorectal cancer progression reveal how LIM kinase 1 (LIMK1) physically interacts with cytoskeletal machinery like myosin-9 and alpha-actinin-4 to drive EMT and cell motility.
This physical remodeling is often governed by the RhoA-ROCK pathway, which acts as a mechanical engine for cell deformation. As shown by Jing Yuan et al. in SHROOM2 inhibits tumor metastasis through RhoA–ROCK pathway-dependent and -independent mechanisms in nasopharyngeal carcinoma, proteins like SHROOM2 normally restrict metastasis by stabilizing this mechanical axis; its disruption allows cancer cells to deform and migrate. Genetic variations can also flip this switch: Jie Mei et al. in A DAAM1 3′-UTR SNP mutation regulates breast cancer metastasis through affecting miR-208a-5p-DAAM1-RhoA axis identified a single-nucleotide polymorphism that prevents a regulatory microRNA from silencing DAAM1, leading to overactive RhoA signaling and accelerated breast cancer dissemination.
The Regulatory Relay: Non-Coding RNA Networks
What triggers these downstream transcription factors and structural shifts? A complex upstream regulatory network composed of non-coding RNAs—specifically long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs)—acts as a system of "molecular sponges." These non-coding RNAs contain binding sites that match and sequester protective microRNAs (miRNAs), preventing them from silencing oncogenic targets.
[ lncRNA / circRNA ] --( Sponges / Inhibits )--> [ Protective miRNA ] --( Fails to Suppress )--> [ Oncogene Active ] --> Metastasis
Consider the relay mapped out by Bing Liu et al. in LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway: the lncRNA LINC01296 sponges the protective miR-26a, which unblocks the enzyme GALNT3, ultimately activating downstream survival pathways.
A similar mechanism is observed with circular RNAs, which are highly stable due to their closed-loop structure. Xia Li et al. in Circular RNA circNRIP1 promotes migration and invasion in cervical cancer by sponging miR-629-3p and regulating the PTP4A1/ERK1/2 pathway show that circNRIP1 sponges miR-629-3p to activate the PTP4A1/ERK1/2 pathway, accelerating cervical cancer invasion.
When therapeutic compounds or natural extracts disrupt these sponges, metastasis can be halted. For example, Jia Li et al. in Effect of paeonol on proliferation, apoptosis, migration, invasion and glutamine of gastric cancer cells via circSFMBT2/miR-665 axis demonstrate that the compound paeonol downregulates the circular RNA circSFMBT2, freeing up miR-665 to suppress gastric cancer migration.
The Intracellular Engine: PI3K/Akt and Matrix Degradation
Once the regulatory brakes are removed, the primary intracellular engine driving cell survival, growth, and migration is the PI3K/Akt/mTOR pathway. This pathway acts as a central hub integrating upstream signals to promote metastatic progression.
Huijuan Shi et al. in miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway illustrate that when tumor suppressors like miR-218 are depleted, the PI3K/Akt/mTOR pathway runs unchecked. This hyperactivation does not just keep cells alive; it actively equips them to invade surrounding tissues by upregulating matrix metalloproteinases (MMPs)—enzymes that act as molecular scissors to chew through the extracellular matrix. The authors show that miR-218 loss leads to an increase in the matrix-degrading enzyme MMP9.
The critical role of MMPs in physical invasion is further supported by Wei Li et al. in Golgi phosphoprotein 3 regulates metastasis of prostate cancer via matrix metalloproteinase 9, who found that GOLPH3 drives prostate cancer metastasis specifically by upregulating MMP9. Similarly, Chunwa Jiang in Membranous type matrix metalloproteinase 16 induces human prostate cancer metastasis demonstrates that the membrane-bound enzyme MMP16 is indispensable for prostate cancer cell invasion.
Furthermore, the PI3K/Akt pathway can reshape the surrounding immune microenvironment to facilitate distant colonization. Shipeng Dai et al. in miR-455/GREM1 axis promotes colorectal cancer progression and liver metastasis by affecting PI3K/AKT pathway and inducing M2 macrophage polarization show that activation of this pathway induces M2 macrophage polarization, effectively reprogramming local immune cells to shield the tumor and assist in colorectal cancer liver metastasis.
Therapeutic Implications: Targeting the Metastatic Compartment
Understanding these precise molecular cascades exposes a critical flaw in traditional oncology: therapies designed against primary tumors often fail to stop metastatic disease. This occurs because primary and metastatic cells operate under distinct evolutionary constraints and environments.
Zhe Jiang et al. in Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer provide a clear explanation for this discrepancy, demonstrating that primary and metastatic breast cancers are driven by distinct, compartment-enriched oncogenic networks. Targeting drivers that are only enriched in primary tumors fails to address the unique adaptations that allow metastatic cells to survive in distant organs.
To combat this, researchers are developing strategies that specifically target the shared or metastatic-specific machinery. For instance, Marie-Anne Goyette et al. in AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer used a gene signature of the metastasis driver AXL to repurpose phenothiazine antipsychotics, successfully dampening the PI3K/Akt/mTOR pathway and reducing systemic spread.
On the frontier of precision medicine, Zhifen Cui et al. in SCORT–Cas13d Nanotherapy Precisely Targets the ‘Undruggable’ Transcription Factor HoxB13 in Metastatic Prostate Cancer In Vivo developed an advanced CRISPR-Cas13d nanotherapy to directly silence HoxB13, a master regulator of metastatic prostate cancer signaling. By shifting the therapeutic focus from localized tumor mass to the specific molecular cascades of dissemination, these approaches offer a path toward preventing the most lethal phase of cancer progression.